Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin versus atorvastatin for ApoB/ApoA-I ratio reduction after PCI in acute coronary syndrome
2005-002892-34Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rosuvastatin and atorvastatin in acute coronary syndrome (ACS) (2 arms), sponsored by AstraZeneca. Started Sep 2005; status: completed.
02
Drugs
rosuvastatinatorvastatin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2005-002892-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002892-34.